{
    "nctId": "NCT02266173",
    "briefTitle": "Observational Study of Pertuzumab Safety in Participants With Breast Cancer",
    "officialTitle": "Post-Marketing Surveillance of Perjeta in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1130,
    "primaryOutcomeMeasure": "Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-HER2 therapy for metastatic disease with HER2 positivity\n* HER2-positive, locally advanced, inflammatory, or early stage breast cancer (greater than \\[\\>\\]2 centimeters \\[cm\\] in diameter) participants who have never received chemotherapy and surgery for breast cancer\n\nExclusion Criteria:\n\n* Hypersensitivity for pertuzumab (Perjeta) or any of its excipients\n* Contraindications to Perjeta according to SmPC\n* Pregnancy and lactation",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}